Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.26 - $17.63
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$5.23M
Enterprise Value-$4.13M
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit26.31
Enterprise Value/Ebitda0.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA debt-free capital structure removes interest obligations and reduces bankruptcy risk, granting management greater strategic flexibility. Over the next 2–6 months this lowers fixed cash outflows and modestly extends runway versus peers with leverage, aiding financing timing and R&D continuity.
Improving Operating LossesA material improvement in operating losses versus prior years indicates progress in cost control and development efficiency. If sustained, this trend can extend cash runway, reduce near-term funding needs and de-risk execution as programs advance through preclinical/clinical milestones.
Strengthened Governance & IncentivesUpdating long-term incentive agreements and electing directors enhances alignment between management and shareholders. Time‑based vesting and change‑in‑control provisions encourage focus on multi‑year value creation and can improve retention and decision consistency during clinical development.
Bears Say
No Revenue / Negative Gross ProfitAbsent any product revenue or positive gross margins, the company lacks an internal cash-generating engine. This structural shortfall means long-term viability depends on successful clinical outcomes, partnerships, or ongoing financing, raising execution and commercialization risk.
Persistent Cash BurnSustained negative operating and free cash flow of roughly $8M TTM creates a recurring financing requirement. Over months this erodes optionality, forces capital raises or spending cuts, and increases dilution risk unless R&D spend is reduced or non‑dilutive funding secured.
Reliance On Equity Financing (ATM)Ongoing use of ATM equity raises demonstrates dependence on share issuance for liquidity. Structurally, this signals limited internal funding and a likelihood of future dilution until revenue/profitability or durable strategic partnerships provide alternative funding sources.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.26 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $5.23M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 38 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.082.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
16.62% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
81.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---